12 Aptamers for the Diagnosis and Therapy …
373
81. Shaltiel-Karyo R, Frenkel-Pinter M, Egoz-Matia N, Frydman-Marom A, Shalev DE, Segal
D, Gazit E (2010) Inhibiting alpha-synuclein oligomerization by stable cell-penetrating betasynuclein fragments recovers phenotype of Parkinson’s disease model flies. PLoS ONE
5(11):e13863. https://doi.org/10.1371/journal.pone.0013863
82. Kienast T, Heinz A (2006) Dopamine and the diseased brain. CNS Neurol Disord Drug Targets
5(1):109–131
83. Swanson CJ, Perry KW, Koch-Krueger S, Katner J, Svensson KA, Bymaster FP (2006) Effect
of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations
of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology
50(6):755–760. https://doi.org/10.1016/j.neuropharm.2005.11.022
84. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, Obeso JA
(2009) Initial clinical manifestations of Parkinson’s disease: features and pathophysiological
mechanisms. Lancet Neurol 8(12):1128–1139. https://doi.org/10.1016/S1474-4422(09)702
93-5
85. Zheng J, Zhou X (2007) Sodium dodecyl sulfate-modified carbon paste electrodes for selective
determination of dopamine in the presence of ascorbic acid. Bioelectrochemistry 70(2):408–
415. https://doi.org/10.1016/j.bioelechem.2006.05.011
86. Mannironi C, Di Nardo A, Fruscoloni P, Tocchini-Valentini GP (1997) In vitro selection of
dopamine RNA ligands. Biochemistry 36(32):9726–9734. https://doi.org/10.1021/bi9700633
87. Liew FF, Hasegawa T, Fukuda M, Nakata E, Morii T (2011) Construction of dopamine sensors
by using fluorescent ribonucleopeptide complexes. Bioorg Med Chem 19(15):4473–4481.
https://doi.org/10.1016/j.bmc.2011.06.031
88. Annoni C, Nakata E, Tamura T, Liew FF, Nakano S, Gelmi ML, Morii T (2012) Construction of
ratiometric fluorescent sensors by ribonucleopeptides. Org Biomol Chem 10(44):8767–8769.
https://doi.org/10.1039/c2ob26722e
89. Liu S, Xing X, Yu J, Lian W, Li J, Cui M, Huang J (2012) A novel label-free electrochemical aptasensor based on graphene-polyaniline composite film for dopamine determination.
Biosens Bioelectron 36(1):186–191. https://doi.org/10.1016/j.bios.2012.04.011
90. Farjami E, Campos R, Nielsen JS, Gothelf KV, Kjems J, Ferapontova EE (2013) RNA aptamerbased electrochemical biosensor for selective and label-free analysis of dopamine. Anal Chem
85(1):121–128. https://doi.org/10.1021/ac302134s
91. Li BR, Hsieh YJ, Chen YX, Chung YT, Pan CY, Chen YT (2013) An ultrasensitive nanowiretransistor biosensor for detecting dopamine release from living PC12 cells under hypoxic
stimulation. J Am Chem Soc 135(43):16034–16037. https://doi.org/10.1021/ja408485m
92. Aguzzi A, Falsig J (2012) Prion propagation, toxicity and degradation. Nat Neurosci
15(7):936–939. https://doi.org/10.1038/nn.3120
93. Prusiner SB (1998) Prions. Proc Natl Acad Sci USA 95(23):13363–13383. https://doi.org/10.
1073/pnas.95.23.13363
94. Rhie A, Kirby L, Sayer N, Wellesley R, Disterer P, Sylvester I, Gill A, Hope J, James W,
Tahiri-Alaoui A (2003) Characterization of 2’-fluoro-RNA aptamers that bind preferentially
to disease-associated conformations of prion protein and inhibit conversion. J Biol Chem
278(41):39697–39705. https://doi.org/10.1074/jbc.M305297200
95. Sayer NM, Cubin M, Rhie A, Bullock M, Tahiri-Alaoui A, James W (2004) Structural determinants of conformationally selective, prion-binding aptamers. J Biol Chem
279(13):13102–13109. https://doi.org/10.1074/jbc.M310928200
96. Weiss S, Proske D, Neumann M, Groschup MH, Kretzschmar HA, Famulok M, Winnacker
EL (1997) RNA aptamers specifically interact with the prion protein PrP. J Virol 71(11):8790–
8797
97. Proske D, Gilch S, Wopfner F, Schatzl HM, Winnacker EL, Famulok M (2002) Prion-proteinspecific aptamer reduces PrPSc formation. Chembiochem Eur J Chem Biol 3(8):717–725.
https://doi.org/10.1002/1439-7633(20020802)3:8%3c717:AID-CBIC717%3e3.0.CO;2-C
98. Sekiya S, Noda K, Nishikawa F, Yokoyama T, Kumar PK, Nishikawa S (2006) Characterization and application of a novel RNA aptamer against the mouse prion protein. J Biochem
139(3):383–390. https://doi.org/10.1093/jb/mvj046
373
81. Shaltiel-Karyo R, Frenkel-Pinter M, Egoz-Matia N, Frydman-Marom A, Shalev DE, Segal
D, Gazit E (2010) Inhibiting alpha-synuclein oligomerization by stable cell-penetrating betasynuclein fragments recovers phenotype of Parkinson’s disease model flies. PLoS ONE
5(11):e13863. https://doi.org/10.1371/journal.pone.0013863
82. Kienast T, Heinz A (2006) Dopamine and the diseased brain. CNS Neurol Disord Drug Targets
5(1):109–131
83. Swanson CJ, Perry KW, Koch-Krueger S, Katner J, Svensson KA, Bymaster FP (2006) Effect
of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations
of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology
50(6):755–760. https://doi.org/10.1016/j.neuropharm.2005.11.022
84. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, Obeso JA
(2009) Initial clinical manifestations of Parkinson’s disease: features and pathophysiological
mechanisms. Lancet Neurol 8(12):1128–1139. https://doi.org/10.1016/S1474-4422(09)702
93-5
85. Zheng J, Zhou X (2007) Sodium dodecyl sulfate-modified carbon paste electrodes for selective
determination of dopamine in the presence of ascorbic acid. Bioelectrochemistry 70(2):408–
415. https://doi.org/10.1016/j.bioelechem.2006.05.011
86. Mannironi C, Di Nardo A, Fruscoloni P, Tocchini-Valentini GP (1997) In vitro selection of
dopamine RNA ligands. Biochemistry 36(32):9726–9734. https://doi.org/10.1021/bi9700633
87. Liew FF, Hasegawa T, Fukuda M, Nakata E, Morii T (2011) Construction of dopamine sensors
by using fluorescent ribonucleopeptide complexes. Bioorg Med Chem 19(15):4473–4481.
https://doi.org/10.1016/j.bmc.2011.06.031
88. Annoni C, Nakata E, Tamura T, Liew FF, Nakano S, Gelmi ML, Morii T (2012) Construction of
ratiometric fluorescent sensors by ribonucleopeptides. Org Biomol Chem 10(44):8767–8769.
https://doi.org/10.1039/c2ob26722e
89. Liu S, Xing X, Yu J, Lian W, Li J, Cui M, Huang J (2012) A novel label-free electrochemical aptasensor based on graphene-polyaniline composite film for dopamine determination.
Biosens Bioelectron 36(1):186–191. https://doi.org/10.1016/j.bios.2012.04.011
90. Farjami E, Campos R, Nielsen JS, Gothelf KV, Kjems J, Ferapontova EE (2013) RNA aptamerbased electrochemical biosensor for selective and label-free analysis of dopamine. Anal Chem
85(1):121–128. https://doi.org/10.1021/ac302134s
91. Li BR, Hsieh YJ, Chen YX, Chung YT, Pan CY, Chen YT (2013) An ultrasensitive nanowiretransistor biosensor for detecting dopamine release from living PC12 cells under hypoxic
stimulation. J Am Chem Soc 135(43):16034–16037. https://doi.org/10.1021/ja408485m
92. Aguzzi A, Falsig J (2012) Prion propagation, toxicity and degradation. Nat Neurosci
15(7):936–939. https://doi.org/10.1038/nn.3120
93. Prusiner SB (1998) Prions. Proc Natl Acad Sci USA 95(23):13363–13383. https://doi.org/10.
1073/pnas.95.23.13363
94. Rhie A, Kirby L, Sayer N, Wellesley R, Disterer P, Sylvester I, Gill A, Hope J, James W,
Tahiri-Alaoui A (2003) Characterization of 2’-fluoro-RNA aptamers that bind preferentially
to disease-associated conformations of prion protein and inhibit conversion. J Biol Chem
278(41):39697–39705. https://doi.org/10.1074/jbc.M305297200
95. Sayer NM, Cubin M, Rhie A, Bullock M, Tahiri-Alaoui A, James W (2004) Structural determinants of conformationally selective, prion-binding aptamers. J Biol Chem
279(13):13102–13109. https://doi.org/10.1074/jbc.M310928200
96. Weiss S, Proske D, Neumann M, Groschup MH, Kretzschmar HA, Famulok M, Winnacker
EL (1997) RNA aptamers specifically interact with the prion protein PrP. J Virol 71(11):8790–
8797
97. Proske D, Gilch S, Wopfner F, Schatzl HM, Winnacker EL, Famulok M (2002) Prion-proteinspecific aptamer reduces PrPSc formation. Chembiochem Eur J Chem Biol 3(8):717–725.
https://doi.org/10.1002/1439-7633(20020802)3:8%3c717:AID-CBIC717%3e3.0.CO;2-C
98. Sekiya S, Noda K, Nishikawa F, Yokoyama T, Kumar PK, Nishikawa S (2006) Characterization and application of a novel RNA aptamer against the mouse prion protein. J Biochem
139(3):383–390. https://doi.org/10.1093/jb/mvj046